Vaccine News and Research

Latest Vaccine News and Research

Antisense therapy shows promise in treating toxoplasmosis

A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.

14 Aug 2012

Six manufacturers receive FDA approval to produce 2012-2013 flu vaccines

The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.

14 Aug 2012

Researchers solve hepatitis C vaccine mystery

Researchers at the Burnet Institute have solved a hepatitis C vaccine mystery which, once developed could be the first ever preventative vaccine for the virus.

13 Aug 2012

World needs a business plan to end AIDS

In this post in Global Post's "Global Pulse" blog, Mitchell Warren, executive director of AVAC, a leading HIV prevention advocacy organization, and Chris Collins, vice president and director of public policy at amfAR, the Foundation for AIDS Research, write that "the world needs a business plan to end AIDS."

13 Aug 2012

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Antigen Discovery, Inc. today announced that it has received a Phase II Small Business Innovation and Research award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens.

13 Aug 2012

Viewpoints: Democrats must get tough on entitlements; Fla. Gov. Scott says feds should stay out of state Medicaid decisions

Democrats nurtured entitlements, which provided a bedrock of security for Americans. But we never said no to entitlement expansion or benefit increases. We haven't supplied enough discipline, and they are out of control. Conversely, we've ignored the New Frontier investment programs, bragging about them but meting out only subsistence rations. They're now stunted and need higher rations. We have one more chance. The fiscal cliff was designed to force tough choices.

12 Aug 2012

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax rPA anthrax vaccine program has been placed on clinical hold.

12 Aug 2012

Breakthrough vaccine against deadly Nipah virus

A major breakthrough in the development of a highly effective vaccine against the deadly Nipah virus has been reported by a team of federal and university scientists. The results of their study, "A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge," will appear in Science Translational Medicine online.

10 Aug 2012

Accurate vaccination needed to protect children

This year the U.S. has seen the worst outbreak of whooping cough in more than 50 years. In fact, it has reached epidemic levels in many states and the Centers for Disease Control and Prevention said the numbers of cases reported is already twice as many as last year. With kids getting ready to head back-to-school, the numbers of children impacted or killed by this disease could continue to rise if children aren't accurately vaccinated.

10 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Pathologist identifies HPV DNA fragments in post-mortem samples after Gardasil vaccination

According to Norma Erickson, President of SaneVax Inc., testimony provided for a coroner's inquest into the death of Jasmine Renata in New Zealand by Dr. Sin Hang Lee, a pathologist on the medical staff at Connecticut's Milford Hospital, revealed the discovery of HPV DNA fragments in post-mortem samples 6 months after Gardasil vaccination.

9 Aug 2012

Viewpoints: Medicaid is key to health law success; OPM weighs changes to FEHB

The Congressional Budget Office recently estimated that 30 million Americans still will be left without health insurance in 2022, after the U.S. Supreme Court ruling that largely upheld President Obama's healthcare plan. The part of the plan that was not upheld by the high court, however, contains the key to lowering that number.

8 Aug 2012

Review explores whether HPV vaccination of young men is warranted and cost effective

Vaccination against human papilloma virus (HPV) is recommended for young women to protect them from HPV infection and cervical cancer. Male HPV immunization is increasingly a topic of debate in the medical community. A timely review of the literature published in Viral Immunology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, explores whether HPV vaccination of young men is warranted and cost effective.

8 Aug 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Advances in HIV/AIDS therapy and the International AIDS Conference: an interview with Professor Sharon Lewin

The anti-HIV drugs, also known as anti-retroviral therapy, came about in the mid ‘90’s. These involved using at least 3 different drugs together.

7 Aug 2012

Commercial cattle vaccine can effectively reduce levels of E. coli by more than 50%

A commercial vaccine for cattle can effectively reduce levels of E. coli by more than 50 percent, a Kansas State University study has found. The vaccine is also effective using two doses instead of the recommended three doses, which can help cut costs for the beef industry.

7 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Genocea Biosciences announced today the presentation of new data supporting its novel approach to developing a first-in-class, protein subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2).

6 Aug 2012

Vaccine News and Research

Latest Vaccine News and Research

Antisense therapy shows promise in treating toxoplasmosis

Six manufacturers receive FDA approval to produce 2012-2013 flu vaccines

Researchers solve hepatitis C vaccine mystery

World needs a business plan to end AIDS

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Viewpoints: Democrats must get tough on entitlements; Fla. Gov. Scott says feds should stay out of state Medicaid decisions

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

Breakthrough vaccine against deadly Nipah virus

Accurate vaccination needed to protect children

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Pathologist identifies HPV DNA fragments in post-mortem samples after Gardasil vaccination

Viewpoints: Medicaid is key to health law success; OPM weighs changes to FEHB

Review explores whether HPV vaccination of young men is warranted and cost effective

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

BioDiem granted European patent for antimicrobial drug

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Advances in HIV/AIDS therapy and the International AIDS Conference: an interview with Professor Sharon Lewin

Commercial cattle vaccine can effectively reduce levels of E. coli by more than 50%

New research center to expedite study of gene transfer approach

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in